GlassScriptPhysician profile
Gregory Alan Foote
NPI 1225562655
$34,590.67
in general payments reported to CMS, 2019-2025
28 companies · $17K in 2025
The $17K reported for 2025 was more than what 97% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,096 · 2021: $5,051 · 2022: $1,689 · 2023: $942 · 2024: $8,414 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $2,515 · Food and Beverage: $2,354 · Education: $541 · Long Term Medical Supply Or Device Loan: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,164.00 |
| Travel and Lodging | $2,515.08 |
| Food and Beverage | $2,353.55 |
| Education | $540.84 |
| Long Term Medical Supply Or Device Loan | $181.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $11,834.60 | 2022-2025 | Motoband, Fibergraft Aeridyan Matrix, Hammerlock |
| Medical Device Business Services, INC. | $10,647.75 | 2024-2025 | Motoband |
| Arthrex, INC. | $6,032.55 | 2020-2022 | |
| Synthes USA Products LLC | $2,170.00 | 2024 | |
| Stryker Corporation | $1,646.49 | 2020-2025 | Inbone, Augment Injectable, Alphavent |
| Mvp Orthopedics INC | $400.07 | 2021-2022 | |
| Integra Lifesciences Corporation | $326.72 | 2021-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Wardlow Enterprises | $251.80 | 2022-2023 | |
| Smith+Nephew, INC. | $168.63 | 2023-2024 | Grafix Pl, Stravix, Oasis |
| Horizon Therapeutics Plc | $162.49 | 2021-2022 | |
| Prism Medical | $134.45 | 2024-2025 | |
| Treace Medical Concepts, INC. | $115.96 | 2022-2024 | |
| Paragon 28, INC. | $103.74 | 2020 | |
| Organogenesis INC. | $82.63 | 2024-2025 | Apligraf |
| Bioventus LLC | $62.50 | 2021-2025 | Exogen Ultrasound Bone Healing System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bone Support INC. | $61.09 | 2024 | Cerament G, Ceramentbone Void Filler |
| Kerecis Limited | $51.85 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Averitas Pharma INC. | $51.40 | 2024-2025 | Qutenza |
| Abbvie INC. | $48.92 | 2022-2025 | |
| Si-Bone, INC. | $35.21 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $34.76 | 2025 | |
| Medtronic, INC. | $34.63 | 2022-2023 | Intellis Adaptivestim |
| Urgo Medical North America, LLC | $30.71 | 2024 | Urgoclean Ag |
| Metric Medical Devices, INC. | $30.02 | 2022 | |
| Aroa Biosurgery Incorporated | $26.38 | 2022 | |
| Biotissue Holdings INC. | $17.44 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.07 | 2024 | Nuzyra |
| Spr Therapeutics, INC | $10.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Foote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.